İnvaziv Aspergilloz Tedavisi

Yıl 2018, Cilt: 6 Sayı: 2, 64 - 82, 12.09.2018

İlknur Erdem , Mustafa Doğan Ridvan Karaali , Şenay Elbasan Omar Enes Ardıç

Öz

İnvaziv aspergilloz (İA), Aspergillus türü mantarların neden
olduğu genellikle immünyetmezlikli hastalarda görülen ve
yüksek mortalite ile seyreden bir enfeksiyon hastalığıdır.
En sık akciğer etkilenmekle birlikte mantar vücudun diğer
organlarına da yayılarak hastalık yapabilir. Tedavisinde
halen vorikonazol birinci seçenek antifungaldir.
Vorikonazol alamayacak ya da vorikonazole cevap
vermeyen hastalarda tedavide alternatif olarak
isavukonazol, itrakonazol, amfoterisin B lipid
formülasyonu, itrakonazol, kaspofungin, mikafungin ve
posakonazol kullanılabilir. Bu yazıda invaziv aspergilloz
tedavisi gözden geçirilmiştir.

Anahtar Kelimeler

aspergillozis, İnvaziv aspergilloz

Kaynakça

• KAYNAKLAR 1.Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327–360. 2.Stevens DA, Kan VL, et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis 2000; 30:696-709. 3. Patterson TF, Thompson GR 3 rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JH, Bennett JE. Executive summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016 Aug 15; 63(4):433-42. Doi:10.1093/cid/ciw444.
• 4.Karthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin – Review of the literature. Eur J Med Res 2011;16: 145-152. 5.Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7–14. 6.Traunmüller F, Popovic M, Konz KH, Smolle-Jüttner FM , Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 2011;88:213–224. 7.Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002; 45:406–407. 8.Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39:192–198. 9.Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 Aug 8;347(6):408-415. 10.Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68(6): 906–915. 11.Traunmüller F, Popovic M, Konz KH, Smolle-Jüttner FM , Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 2011;88:213–224 12.Cornely OA, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94(1):113-122. 13.Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al.. Liposomal Amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high–loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007; 44: 1289-1297. 14. Cesar JMS, Resende JS, Amaral NF, Alves CMS, Vilhena AF and Silva FL. Cavernostomy x Resection for pulmonary aspergilloma: A 32-year history. J Cardiothorac Surg 2011; 6:129. 15.Chen J, Chang Y, Luh S, Lee J, Lee Y. Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax 1997;52:810–813. 16.Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: a review of a disease with a worldwide distribution. J Asthma 2002;39(4):273-289. 17.Agarwal R, Khan A, Garg M, Aggarwal AN, Gupta D. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. World J Radiol 2012; 4(4): 141-150. 18.Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952–957. 19.Fernandez IJ, Stanzani M, Tolomelli G, Pasquini E, Vianelli N, Baccarani M, Sciarretta V. Sinonasal risk factors for the development of invasive fungal sinusitis in hematological patients: Are they important?. Allergy Rhinol (Providence) 2011; 2(1): 6–11. 20.Mohindra S, Mohindra S, Bal A. Allergic fungal sinusitis: innocence under suspicion. Med Mycol 2012; 50(2):179-186. 21.Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis and management. Med Mycol 2009; 47:324-330. 22.Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22:258–266. 23.Krenke R, Grabczak EM. Tracheobronchial manifestations of aspergillus infections. The Scientific World Journal 2011; 2310–2329. 24. Borro JM, Solé A, de la Torre M, Pastor A, Fernandez R, Saura A, Delgado M, Monte E, Gonzalez D. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. 2008;40(9):3090-3093. 25. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8:13–20. 26. Menasalvas A, Bouza E. Infective endocarditis caused by unusual organisms. Rev Esp Cardiol 1998;51:79-85. 27. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. Chest 2002; 122:302-310. 28. Rubinstein E, Lang R. Fungal Endocarditis. Eur Heart J 1995;16:84-89. 29. Kalokhe AS, Rouphael N, El Chami MF, Workowski KA, Ganesh G, Jacob JT. Aspergillus endocarditis: a review of the literatüre. Int J Infect Dis 2010; 14(12):1040-1047. 30. Kothari A, Pillai BS, Bhan A. Pacing lead endocarditis due to Aspergillus fumigatus. Indian J Med Microbiol 2010; 28:72-73. 31. Torre-Cisneros J, Lopez OL, Kusne S, Martinez AJ, Starzl TE, Simmons RL, Martin M. CNS aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1993; 56(2):188-193. 32. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literatüre. Clin Infect Dis 2001; 32(3):358-366. 33. Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infec Dis 2004; 8:103-110. 34. Paterson DL. New clinical presentations of invasive aspergillosis in non-conventional hosts. Clin Microbiol Infec Dis 2004; 10:24–30. 35. Dotis J, Roilides E. Osteomyelitis due to Aspergillus species in chronic granulomatous disease: an update of the literature. Mycoses 2011;54(6):686-696. 36. Vinas FC, King PK, Diaz FG. Spinal aspergillus osteomyelitis. Clin Infect Dis 1999; 28: 1223–1229. 37. Studemeister A, Stevens DA. Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. Clin Infec Dis 2011; 52(1):1-6. 38. Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005; 40:1141–1147. 39. Kirby A, Hassan I, Burnie J. Recommendations for managing aspergillus osteomyelitis and joint infections based on a review of the literature. J Infect 2006; 52:405–414. 40. Lodge BA, Ashley ED, Steele MP, Perfect JR. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 2004; 342:1376–1378. 41. Chakrabarti A, Chatterjee S, Radotra BD. Cutaneous and wound aspergillosis. In: Pasqualotto AC ( ed ). Aspergillosis: from diagnosis to prevention. Springer, Dordrecht, 2009, 939-959. 42. Ben-Ami R, Lewis RE, Leventakos K, Latgé JP, Kontoyiannis DP. Cutaneous model of invasive aspergillosis . Antimicrob Agents Chemother 2010; 54(5): 1848–1854. 43. Hori A, Kami M, Kishi Y, Machida U, Matsumura T, Kashima T. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: A retrospective autopsy-based study of 107 patients. J Hosp Infect 2002; 50:175–182. 44. Jombo GTA, Banwat EB, Gyoh SK. Pulmonary and extra pulmonary manifestations of aspergillosis in clinical practice and potential challenges in management: An analysis of literature review. J Clin Med Res 2010; 2(11):185-193. 45. Bai QX, Huan Y, Wang JH, Yang LJ, Dong HJ. Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a non-immunocompromised patient. Int J Mol Sci 2012; 13:11063-11070. 46. Metta H, Corti M, Redini L, Bruggesser F, Arechavala A, Negroni R, Veliz L. Renal abscess due to Aspergillus fumigatus as the only sign of disseminated aspergillosis in a patient with AIDS. Rev Iberoam Micol 2010; 30;27(3):136-139. 47. Oosten AW, Sprenger HG, van Leeuwen JT, Meessen NE, van Assen S. Bilateral renal aspergillosis in a patient with AIDS: a case report and review of reported cases. AIDS Patient Care STDS. 2008; 22(1):1-6. 48. Lisson SW, Hellinger WC, Parra RO. Primary bilateral parenchymal renal Aspergillus infection. Urology 2002; 60:345. 49. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47:226–235. 50. Roilides E, Lyman CA, Filioti J, et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46:1974–1976. 51. Bates DW, Su L, Yu DT, et al . Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693. 52. Patterson TF.Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles. Med Mycol 2006; 44:357-362. 53. Arnold TM , Dotson E, Sarosi GA, Hage CA. Traditional and emerging antifungal therapies. Proc Am Thorac Soc Vol 2010; 7:222-228. 54. Walsh JT, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacocinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487-496. 55. Herbrecht R, Natarajan-Amé S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003 Aug;4(8):1277-1287. 56. Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Time for a new “gold standard”. Clin Infect Dis 2003; 37:415-425. 57. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32:686-693 58. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrobial Agents. 2006;27:S36-S44. 59. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebocontrolled trial. Clin Infect Dis. 2008;46:1401-1408. 60. Perfect JR. Aerosolized antifungal prophylaxis: The winds of change? Clin Infect Dis. 2008;46:1409-1411. 61. Quindós G, Carrillo-Muñoz AJ, Ruesga MT, Alonso-Vargas R, Miranda Y, Tur-Tur C, Rubio M, Wallace TL, Cossum PA, Martín-Mazuelos E, Cisterna R, Pontón J. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis 2000; 19(8):645-648. 62. Offner F, Krcmery V, Boogaerts M, Doyen C, Engelhard D, Ribaud P, Cordonnier C, de Pauw B, Durrant S, Marie JP, Moreau P, Guiot H, Samonis G, Sylvester R, Herbrecht R; EORTC Invasive Fungal Infections Group. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother. 2004; 48(12):4808-4812. 63. Lestner J, Hope WW. Itraconazole : an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin Drug Metab Toxicol. May 2013 (doi:10.1517/17425255.2013.794785). 64. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001, 33(8):83-90. 65. Lewis RE. Current concepts in antifungal pharmacology. Symposium on Antimicrobial Therapy Mayo Clin Proc 2011;86 (8):805-817. 66. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630–637. 67. Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011:4 43–53. 68. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649–663. 69. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546–2553. 70. Boucher HW, Groll AH, Chiou CC et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2000. 71. Herbrecht R, Flückiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Antifungal therapy in leukemia patients. UPDATE ECIL 4 2011. 72. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG: In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343–2345. 73. Saag MS, Dısmukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988; 1-8. 74. Sanatı H, Belanger P, Frattı R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol. Biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 2492–2496. 75. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150 ( 3 ):101–115. 76. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954–958. 77. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17:573–575. 78. Simitsopoulou M, Ioannidis J, Kanellou K, Orfanou A, Walsh TJ, Roilides E. Differential immunomodulatory effects of voriconazole on Toll-like receptors (TLR) 2 and 4 and nuclear factor KB in human monocytes [abstract M737]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). American Society for Microbiology, 2007:437. 79. Theuretzbacher U, Ihle F. Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649–663. 80. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, Chen Y, Hu DL, Wang D, Zhou HH. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009; 65: 281–285. 81. Brüggemann RJM, Alffenaar JC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441–1458. 82. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211. 83. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010; 69: 222–230. 84. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N: Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166–2172. 85. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, Buclin T, Majcherczyk PA, Sanglard D, Marchetti O. Variability of voriconazole plasma levels measured by new highperformance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 51:137–143. 86. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532–1535. 87. Walsh TJ, Driscoll TA, Groll AH, Arrieta AC, Klein N, Bradley J, Jafri HS, Schlamm HT, Troke PF, Wood N, et al. Population Pharmacokinetic (POP-PK) analysis of voriconazole (VRC): developing a rationale for dosage in pediatric patients. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL (M-620). September 2007. 88. Trifilio S, Pennick G, Pi J, Zook J, et al. Monitoring voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell recipients. Cancer 2007; 109 (8):1532-1535. 88. Ina Scholz, Heike Oberwittler, Klaus-Dieter Riedel, Jürgen Burhenne, Johanna Weiss, Walter E Haefeli, Gerd Mikus. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68 (6): 906–915 90. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6) :408-415. 91. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood 2005; 106(8):2641-2645. 92. Böhme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S, Heussel G, Heussel C, Junghanss C, Kern WK, Kubin T, Maschmeyer G, Sezer O, Silling G, Südhoff T, Szelenyi H, Ullmann AJ: Treatment of fungal infections in hematology and oncology. Ann Hematol 2003; 82 (2):133–140. 93. Vehreschild JJ, Böhme A, Buchheidt D, et al. A doubleblind trial on prophylactic voriconazole or placebo during induction chemotherapy for acute myelogenous leukaemia. J Infect. 2007; 55 (5):445-449. 94. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797–802. 95. Wingard JR, Carter SL, Walsh TJ, et al. Blood an marrow transplant clinical trials network. Randomized, doubleblind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hemato poietic cell transplantation. Blood 2010; 116 (24): 5111-5118. 96. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570–1572. 97. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235–243. 98. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39:1241–1244. 99. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42:1859–1864. 100. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 1570–1572. 101. Traunmüller F, Popovic M, Konz KH, Smolle-Jüttner FM , Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 2011; 88:213–224. 102. Herbrecht R: Voriconazole: Therapeutic review of a new azole antifungal. Expert Rev Anti-Infect Ther 2004; 2: 485–497. 103. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44:55–56. 104. Cowen EW, Nguyen JC, Miller DD, McShane D, Arron ST, Prose NS, Turner ML, Fox LP. Chronic Phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31–37. 105. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated With long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146:300–304. 106. Morice C, Acher A, Soufir N, Michel M, Comoz F, Leroy D, Verneuil L. Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report. Case Report Med 2010; 2010: 351084. Epub 2010 Dec 16. 107. Patterson TF. Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles? Med Mycol 2006; 44 (Suppl 1): 357-362. 108. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415. 109. Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis –review of the literature. Eur J Med Res 2011; 16: 139-144. 110. Li Y, Theuretzbacher U, Clancy CJ et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010; 49: 379-396. 111. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356 (4):348-359. 112. Türel O. Newer antifungal agents. Expert Rev Anti Infect Ther. 2011 Mar;9(3):325-38. 113. Natesan SK, Chandrasekar PH. Isavuconazole fort he treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug resist 2016;9: 291-300 114. Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Adv Ther 2017; 34: 207-220.doi: 10.1007/s12325-016-0443-1. Epub 2016 Dec 2.
• 115. Ledoux MP , Toussaint E , Denis J, Herbrecht R. New pharmacological opportunities for the treatment of invasive mould diseases. J Antimicrob Chemother 2017; 72 Suppl 1: i48–i58 doi:10.1093/jac/dkx033.
• 116. Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R. ECIL-6 Guidelines For The Treatment Of Invasive Candidiasis, Aspergillosis And Mucormycosis In Leukemia And Hematopoietic Stem Cell Transplant Patients. Haematologica March 2017 102: 433-444; Doi:10.3324/ haematol.2016.152900.
• 117. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J, Infectious Disease Group of the EORTC: An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274–1281.
• 118. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S , Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat J, Herbrecht R: Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176–1184. 119. Heinz WJ, Buchheidt D, Ullmann AJ. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections. Mycoses 2016; 59: 480-93. Doi: 10.1111/myc.12477. Epub 2016 Jun 21. 120. Wagner C, Graninger W, Presterl E, Joukhadar C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78: 161–177. 121. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571. 122. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337–349. 123. Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K, Miyazaki Y, Yoshinari T, Kartsonis NA, Niki Y. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis. 2013 Mar;32 (3):387-397. 124. Kofla G and Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literatüre. Eur J Med Res. 2011; 16(4): 159–166. 125. Gadea I, Mensa J. Potential of anidulafungin in combined therapy (in Spanish). Enferm Infec Microbiol Clin 2008; 26 (suppl 14):51–55. 126. Steinbach WJ, Juvvadi PR, Fortwendel JR, Rogg LE. Newer combination antifungal therapies for invasive aspergillosis. Med Mycol 2011; 49 ( Suppl 1): 77-81. 127. Karthaus M, Buchheidt D. Invasive aspergillosis: new insight into disease, diagnostic and treatment. Curr Pharm Des 2013; 19: 3569-3594.